Abstract
Twenty-six patients with metastases from a germinal cancer of the testis were treated with Mithramycin. After an observation time of between 1/2-31/2 years, 18 are still alive, of which 12 appear to be free from cancer. The 2-year survival rate is 50% (5/10). The side effects of Mithramycin therapy are described and discussed.